Tumor mutational burden assessed by a targeted NGS assay predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer

被引：0
|
作者：
Jermann, P. [1 ]
Alborelli, I. [1 ]
Leonards, K. [1 ]
Rothschild, S. I. [2 ]
Leuenberger, L. [1 ]
Prince, S. Savic [1 ]
Mertz, K. [3 ]
Poechtrager, S. [3 ]
Zippelius, A. [2 ]
Quagliata, L. [4 ]
Bubendorf, L. [1 ]
机构：
[1] Univ Hosp Basel, Inst Pathol, Basel, Switzerland
[2] Univ Spital Basel, Basel, Switzerland
[3] Kantonsspital Liestal, Med Univ Klin, Liestal, Switzerland
[4] Univ Spital Basel, Pathol, Basel, Switzerland
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
161P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Immune checkpoint inhibitors in advanced non-small cell lung cancer
    Fabre, Elizabeth
    Pecuchet, Nicola
    Cadranel, Jacques
    BULLETIN DU CANCER, 2016, 103 : S138 - S143
  • [22] Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
    Assi, Hazem I.
    Kamphorst, Alice O.
    Moukalled, Nour M.
    Ramalingam, Suresh S.
    CANCER, 2018, 124 (02) : 248 - 261
  • [23] Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients
    Xi Chen
    Liangjie Fang
    Yanping Zhu
    Zhang Bao
    Qing Wang
    Rong Liu
    Wenjia Sun
    Haiwei Du
    Jing Lin
    Bing Yu
    Songan Chen
    Jianya Zhou
    Jianying Zhou
    Cancer Immunology, Immunotherapy, 2021, 70 : 3513 - 3524
  • [24] Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients
    Chen, Xi
    Fang, Liangjie
    Zhu, Yanping
    Bao, Zhang
    Wang, Qing
    Liu, Rong
    Sun, Wenjia
    Du, Haiwei
    Lin, Jing
    Yu, Bing
    Chen, Songan
    Zhou, Jianya
    Zhou, Jianying
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (12) : 3513 - 3524
  • [25] Comparative analysis of three NGS platforms assessing tumor mutational burden and mutational landscape in resectable non-small cell lung cancer
    Lee, J. B.
    Choi, S. J.
    Kim, J. H.
    Hong, M. H.
    Cho, B. C.
    Lim, S. M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1649 - S1649
  • [26] Immune Checkpoint Inhibitor Score Predicts Survival Benefit of Immunotherapy in Patients with Non-small Cell Lung Cancer
    Kang, Da Hyun
    Choi, Chang-Min
    Park, Cheol-Kyu
    Oh, In-Jae
    Kim, Young-Chul
    Yoon, Seong Hoon
    Kim, Yoonjoo
    Lee, Jeong Eun
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2024, 87 (04) : 483 - 493
  • [27] Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer
    Li Wen-Qian
    Li Ling-Yu
    Bai Ri-Lan
    Qian Lei
    Chen Nai-Fei
    Cui Jiu-Wei
    中华医学杂志英文版, 2020, 133 (21) : 2630 - 2632
  • [28] Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer
    Li, Wen-Qian
    Li, Ling-Yu
    Bai, Ri-Lan
    Qian, Lei
    Chen, Nai-Fei
    Cui, Jiu-Wei
    CHINESE MEDICAL JOURNAL, 2020, 133 (21) : 2630 - 2632
  • [29] Cost-effectiveness of PD-L1 testing and tumor mutational burden testing of immune checkpoint inhibitors for non-small cell lung cancer.
    Li, Wenqian
    Li, Lingyu
    Chen, Naifei
    Cui, Jiuwei
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Tumor mutational burden as a predictive biomarker for non-small cell lung cancer treated with immune checkpoint inhibitors of PD-1/PD-L1
    Shao, Min-min
    Xu, Yue-ping
    Zhang, Jin-jing
    Mao, Mao
    Wang, Meng-chuan
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (06): : 1446 - 1458
12345